New: Introducing the Finviz Futures Map

Purple Biotech Ltd.

Contributing Author

Recent Articles by Purple Biotech Ltd.

Sep-05	Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants PPBT -15.38% GlobeNewswire
Sep-04	Purple Biotech Announces Pricing of Up To $18 Million Public Offering PPBT GlobeNewswire
Sep-04	Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai PPBT GlobeNewswire
Sep-03	Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 PPBT GlobeNewswire
Aug-27	Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PPBT GlobeNewswire
Aug-06	Purple Biotech Reports Second Quarter 2025 Financial Results PPBT GlobeNewswire
Jul-23	Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 PPBT GlobeNewswire
Jun-23	Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress PPBT GlobeNewswire
Jun-17	Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer PPBT GlobeNewswire
Jun-04	Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform PPBT GlobeNewswire
May-21	Purple Biotech Reports First Quarter 2025 Financial Results PPBT GlobeNewswire
May-12	Purple Biotech Appoints Shai Lankry as Chief Financial Officer PPBT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.